These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 11246599

  • 1. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects.
    Foidart JM.
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():25-33. PubMed ID: 11246599
    [Abstract] [Full Text] [Related]

  • 2. Added benefits of drospirenone for compliance.
    Foidart JM.
    Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
    [Abstract] [Full Text] [Related]

  • 3. Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone.
    Oelkers W.
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():17-24. PubMed ID: 11246598
    [Abstract] [Full Text] [Related]

  • 4. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers.
    Oelkers W, Helmerhorst FM, Wuttke W, Heithecker R.
    Gynecol Endocrinol; 2000 Jun; 14(3):204-13. PubMed ID: 10923282
    [Abstract] [Full Text] [Related]

  • 5. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being.
    Boschitsch E, Skarabis H, Wuttke W, Heithecker R.
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600
    [Abstract] [Full Text] [Related]

  • 6. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
    Oelkers WH.
    Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652
    [Abstract] [Full Text] [Related]

  • 7. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A, De Leo V.
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone.
    Huber J, Foidart JM, Wuttke W, Merki-Feld GS, The HS, Gerlinger C, Schellschmidt I, Heithecker R.
    Eur J Contracept Reprod Health Care; 2000 Mar; 5(1):25-34. PubMed ID: 10836660
    [Abstract] [Full Text] [Related]

  • 9. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone.
    Oelkers W.
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():19-26; discussion 42-3. PubMed ID: 12659403
    [Abstract] [Full Text] [Related]

  • 10. Yasmin: the reason why.
    Thorneycroft IH.
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
    [Abstract] [Full Text] [Related]

  • 11. Yasmin--a new oral contraceptive, a new progestogen: the reasons why.
    Mansour D.
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():9-16. PubMed ID: 11246601
    [Abstract] [Full Text] [Related]

  • 12. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel.
    Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R.
    Eur J Contracept Reprod Health Care; 2000 Jun; 5(2):124-34. PubMed ID: 10943575
    [Abstract] [Full Text] [Related]

  • 13. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms.
    Apter D, Borsos A, Baumgärtner W, Melis GB, Vexiau-Robert D, Colligs-Hakert A, Palmer M, Kelly S.
    Eur J Contracept Reprod Health Care; 2003 Mar; 8(1):37-51. PubMed ID: 12725674
    [Abstract] [Full Text] [Related]

  • 14. Pharmacology of different progestogens: the special case of drospirenone.
    Sitruk-Ware R.
    Climacteric; 2005 Oct; 8 Suppl 3():4-12. PubMed ID: 16203650
    [Abstract] [Full Text] [Related]

  • 15. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
    Gaspard U, Endrikat J, Desager JP, Buicu C, Gerlinger C, Heithecker R.
    Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400
    [Abstract] [Full Text] [Related]

  • 16. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.
    Borges LE, Andrade RP, Aldrighi JM, Guazelli C, Yazlle ME, Isaia CF, Petracco A, Peixoto FC, Camargos AF.
    Contraception; 2006 Dec; 74(6):446-50. PubMed ID: 17157100
    [Abstract] [Full Text] [Related]

  • 17. A double blind randomized control trial, comparing effect of drospirenone and gestodene to sexual desire and libido.
    Oranratanaphan S, Taneepanichskul S.
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S17-22. PubMed ID: 17726807
    [Abstract] [Full Text] [Related]

  • 18. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure.
    Yildizhan R, Yildizhan B, Adali E, Yoruk P, Birol F, Suer N.
    Arch Gynecol Obstet; 2009 Aug; 280(2):255-61. PubMed ID: 19125264
    [Abstract] [Full Text] [Related]

  • 19. Is [symbol: see text] Yasmin a "truly different" pill?
    Drug Ther Bull; 2002 Aug; 40(8):57-9. PubMed ID: 12216337
    [Abstract] [Full Text] [Related]

  • 20. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate.
    Charoenvisal C, Thaipisuttikul Y, Pinjaroen S, Krisanapan O, Benjawang W, Koster A, Doesburg W.
    Int J Fertil Menopausal Stud; 1996 Aug; 41(4):423-9. PubMed ID: 8894800
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.